Assessment of type I error rates for the statistical sub-model in NONMEM
The aim of this study was to assess the type I error rate when applying the likelihood ratio (LR) test, for components of the statistical sub-model in NONMEM. Data were simulated from a pharmacokinetic one compartment intravenous bolus model. Two models were fitted to the data, the simulation model...
Gespeichert in:
Veröffentlicht in: | Journal of pharmacokinetics and pharmacodynamics 2002-06, Vol.29 (3), p.251-269 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 269 |
---|---|
container_issue | 3 |
container_start_page | 251 |
container_title | Journal of pharmacokinetics and pharmacodynamics |
container_volume | 29 |
creator | WÄHLBY, Ulrika BOUW, M. Rene JONSSON, E. Niclas KARLSSON, Mats O |
description | The aim of this study was to assess the type I error rate when applying the likelihood ratio (LR) test, for components of the statistical sub-model in NONMEM. Data were simulated from a pharmacokinetic one compartment intravenous bolus model. Two models were fitted to the data, the simulation model and a model containing one additional parameter, and the difference in objective function values between models was calculated. The additional parameter was either (i) a covariate effect on the interindividual variability in CL or V, (ii) a covariate effect on the residual error variability, (iii) a covariance term between CL and V, or (iv) interindividual variability in V. Factors in the simulation conditions (number of individuals and samples per individual, interindividual and residual error magnitude, residual error model) were varied systematically to assess their potential influence on the type I error rate. Different estimation methods within NONMEM were tried. When the first-order conditional estimation method with interaction (FOCE INTER) was used the estimated type I error rates for inclusion of a covariate effect (i) on the interindividual variability, or (ii) on the residual error variability, were in agreement with the type I error rate expected under the assumption that the model approximations made by the estimation method are negligible. When the residual error variability was increased, the type I error rates for (iii) inclusion of covariance between etaCL-etaV were inflated if the underlying residual distribution was lognormal, or if a normal distribution was combined with too little information in the data (too few samples per subject or sampling at uninformative time-points). For inclusion of (iv) etaV, the type I error rates were affected by the underlying residual error distribution; with a normal distribution the estimated type I error rates were close to the expected, while if a non-normal distribution was used the type I errors rates increased with increasing residual variability. When the first-order (FO) estimation method was used the estimated type I error rates were higher than the expected in most situations. For the FOCE INTER method, but not the FO method, the LR test is appropriate when the underlying assumptions of normality of residuals, and of enough information in the data, hold true. Deviations from these assumptions may lead to inflated type I error rates. |
doi_str_mv | 10.1023/A:1020254823597 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_72697947</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2157705731</sourcerecordid><originalsourceid>FETCH-LOGICAL-p264t-788772eab96efb0bd6b9d58616ea914c119cb6c2d0a92b51b0f826dc70abc7fc3</originalsourceid><addsrcrecordid>eNpd0UtLAzEQAOAgiq2PszcJgt5Wk2w2D2-lVFtQe1HwtiTZLG7ZR81kD_33RqwIHoaZw8cwD4QuKLmlhOV3s_uUCCu4Ynmh5QGa0kLmmZKcH37XQmYp3ifoBGBDCBUFI8doQhnnmms1RcsZgAfofB_xUOO423q8wj6EIeBgogdcpyp-eAzRxAZi40yLYbRZN1S-xU2PX9Yvz4vnM3RUmxb8-T6foreHxet8mT2tH1fz2VO2ZYLHTColJfPGauFrS2wlrK4KJajwRlPuKNXOCscqYjSzBbWkVkxUThJjnaxdfopufvpuw_A5eohl14DzbWt6P4xQSia01FwmePUPboYx9Gm2UhaS5EoxntDlHo2281W5DU1nwq78PVAC13tgIG1eB9O7Bv4cT18gOc-_AHmXc1A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>757038824</pqid></control><display><type>article</type><title>Assessment of type I error rates for the statistical sub-model in NONMEM</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>WÄHLBY, Ulrika ; BOUW, M. Rene ; JONSSON, E. Niclas ; KARLSSON, Mats O</creator><creatorcontrib>WÄHLBY, Ulrika ; BOUW, M. Rene ; JONSSON, E. Niclas ; KARLSSON, Mats O</creatorcontrib><description>The aim of this study was to assess the type I error rate when applying the likelihood ratio (LR) test, for components of the statistical sub-model in NONMEM. Data were simulated from a pharmacokinetic one compartment intravenous bolus model. Two models were fitted to the data, the simulation model and a model containing one additional parameter, and the difference in objective function values between models was calculated. The additional parameter was either (i) a covariate effect on the interindividual variability in CL or V, (ii) a covariate effect on the residual error variability, (iii) a covariance term between CL and V, or (iv) interindividual variability in V. Factors in the simulation conditions (number of individuals and samples per individual, interindividual and residual error magnitude, residual error model) were varied systematically to assess their potential influence on the type I error rate. Different estimation methods within NONMEM were tried. When the first-order conditional estimation method with interaction (FOCE INTER) was used the estimated type I error rates for inclusion of a covariate effect (i) on the interindividual variability, or (ii) on the residual error variability, were in agreement with the type I error rate expected under the assumption that the model approximations made by the estimation method are negligible. When the residual error variability was increased, the type I error rates for (iii) inclusion of covariance between etaCL-etaV were inflated if the underlying residual distribution was lognormal, or if a normal distribution was combined with too little information in the data (too few samples per subject or sampling at uninformative time-points). For inclusion of (iv) etaV, the type I error rates were affected by the underlying residual error distribution; with a normal distribution the estimated type I error rates were close to the expected, while if a non-normal distribution was used the type I errors rates increased with increasing residual variability. When the first-order (FO) estimation method was used the estimated type I error rates were higher than the expected in most situations. For the FOCE INTER method, but not the FO method, the LR test is appropriate when the underlying assumptions of normality of residuals, and of enough information in the data, hold true. Deviations from these assumptions may lead to inflated type I error rates.</description><identifier>ISSN: 1567-567X</identifier><identifier>EISSN: 1573-8744</identifier><identifier>DOI: 10.1023/A:1020254823597</identifier><identifier>PMID: 12449498</identifier><language>eng</language><publisher>Dordrecht: Springer</publisher><subject>Analysis of Variance ; Biological and medical sciences ; Computer Simulation - statistics & numerical data ; General pharmacology ; Humans ; Injections, Intravenous - statistics & numerical data ; Likelihood Functions ; Medical sciences ; Models, Statistical ; Nonlinear Dynamics ; Normal distribution ; Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions ; Pharmacology. Drug treatments ; Studies</subject><ispartof>Journal of pharmacokinetics and pharmacodynamics, 2002-06, Vol.29 (3), p.251-269</ispartof><rights>2003 INIST-CNRS</rights><rights>Plenum Publishing Corporation 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14023034$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12449498$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WÄHLBY, Ulrika</creatorcontrib><creatorcontrib>BOUW, M. Rene</creatorcontrib><creatorcontrib>JONSSON, E. Niclas</creatorcontrib><creatorcontrib>KARLSSON, Mats O</creatorcontrib><title>Assessment of type I error rates for the statistical sub-model in NONMEM</title><title>Journal of pharmacokinetics and pharmacodynamics</title><addtitle>J Pharmacokinet Pharmacodyn</addtitle><description>The aim of this study was to assess the type I error rate when applying the likelihood ratio (LR) test, for components of the statistical sub-model in NONMEM. Data were simulated from a pharmacokinetic one compartment intravenous bolus model. Two models were fitted to the data, the simulation model and a model containing one additional parameter, and the difference in objective function values between models was calculated. The additional parameter was either (i) a covariate effect on the interindividual variability in CL or V, (ii) a covariate effect on the residual error variability, (iii) a covariance term between CL and V, or (iv) interindividual variability in V. Factors in the simulation conditions (number of individuals and samples per individual, interindividual and residual error magnitude, residual error model) were varied systematically to assess their potential influence on the type I error rate. Different estimation methods within NONMEM were tried. When the first-order conditional estimation method with interaction (FOCE INTER) was used the estimated type I error rates for inclusion of a covariate effect (i) on the interindividual variability, or (ii) on the residual error variability, were in agreement with the type I error rate expected under the assumption that the model approximations made by the estimation method are negligible. When the residual error variability was increased, the type I error rates for (iii) inclusion of covariance between etaCL-etaV were inflated if the underlying residual distribution was lognormal, or if a normal distribution was combined with too little information in the data (too few samples per subject or sampling at uninformative time-points). For inclusion of (iv) etaV, the type I error rates were affected by the underlying residual error distribution; with a normal distribution the estimated type I error rates were close to the expected, while if a non-normal distribution was used the type I errors rates increased with increasing residual variability. When the first-order (FO) estimation method was used the estimated type I error rates were higher than the expected in most situations. For the FOCE INTER method, but not the FO method, the LR test is appropriate when the underlying assumptions of normality of residuals, and of enough information in the data, hold true. Deviations from these assumptions may lead to inflated type I error rates.</description><subject>Analysis of Variance</subject><subject>Biological and medical sciences</subject><subject>Computer Simulation - statistics & numerical data</subject><subject>General pharmacology</subject><subject>Humans</subject><subject>Injections, Intravenous - statistics & numerical data</subject><subject>Likelihood Functions</subject><subject>Medical sciences</subject><subject>Models, Statistical</subject><subject>Nonlinear Dynamics</subject><subject>Normal distribution</subject><subject>Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions</subject><subject>Pharmacology. Drug treatments</subject><subject>Studies</subject><issn>1567-567X</issn><issn>1573-8744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpd0UtLAzEQAOAgiq2PszcJgt5Wk2w2D2-lVFtQe1HwtiTZLG7ZR81kD_33RqwIHoaZw8cwD4QuKLmlhOV3s_uUCCu4Ynmh5QGa0kLmmZKcH37XQmYp3ifoBGBDCBUFI8doQhnnmms1RcsZgAfofB_xUOO423q8wj6EIeBgogdcpyp-eAzRxAZi40yLYbRZN1S-xU2PX9Yvz4vnM3RUmxb8-T6foreHxet8mT2tH1fz2VO2ZYLHTColJfPGauFrS2wlrK4KJajwRlPuKNXOCscqYjSzBbWkVkxUThJjnaxdfopufvpuw_A5eohl14DzbWt6P4xQSia01FwmePUPboYx9Gm2UhaS5EoxntDlHo2281W5DU1nwq78PVAC13tgIG1eB9O7Bv4cT18gOc-_AHmXc1A</recordid><startdate>20020601</startdate><enddate>20020601</enddate><creator>WÄHLBY, Ulrika</creator><creator>BOUW, M. Rene</creator><creator>JONSSON, E. Niclas</creator><creator>KARLSSON, Mats O</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20020601</creationdate><title>Assessment of type I error rates for the statistical sub-model in NONMEM</title><author>WÄHLBY, Ulrika ; BOUW, M. Rene ; JONSSON, E. Niclas ; KARLSSON, Mats O</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p264t-788772eab96efb0bd6b9d58616ea914c119cb6c2d0a92b51b0f826dc70abc7fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Analysis of Variance</topic><topic>Biological and medical sciences</topic><topic>Computer Simulation - statistics & numerical data</topic><topic>General pharmacology</topic><topic>Humans</topic><topic>Injections, Intravenous - statistics & numerical data</topic><topic>Likelihood Functions</topic><topic>Medical sciences</topic><topic>Models, Statistical</topic><topic>Nonlinear Dynamics</topic><topic>Normal distribution</topic><topic>Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions</topic><topic>Pharmacology. Drug treatments</topic><topic>Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WÄHLBY, Ulrika</creatorcontrib><creatorcontrib>BOUW, M. Rene</creatorcontrib><creatorcontrib>JONSSON, E. Niclas</creatorcontrib><creatorcontrib>KARLSSON, Mats O</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmacokinetics and pharmacodynamics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WÄHLBY, Ulrika</au><au>BOUW, M. Rene</au><au>JONSSON, E. Niclas</au><au>KARLSSON, Mats O</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of type I error rates for the statistical sub-model in NONMEM</atitle><jtitle>Journal of pharmacokinetics and pharmacodynamics</jtitle><addtitle>J Pharmacokinet Pharmacodyn</addtitle><date>2002-06-01</date><risdate>2002</risdate><volume>29</volume><issue>3</issue><spage>251</spage><epage>269</epage><pages>251-269</pages><issn>1567-567X</issn><eissn>1573-8744</eissn><abstract>The aim of this study was to assess the type I error rate when applying the likelihood ratio (LR) test, for components of the statistical sub-model in NONMEM. Data were simulated from a pharmacokinetic one compartment intravenous bolus model. Two models were fitted to the data, the simulation model and a model containing one additional parameter, and the difference in objective function values between models was calculated. The additional parameter was either (i) a covariate effect on the interindividual variability in CL or V, (ii) a covariate effect on the residual error variability, (iii) a covariance term between CL and V, or (iv) interindividual variability in V. Factors in the simulation conditions (number of individuals and samples per individual, interindividual and residual error magnitude, residual error model) were varied systematically to assess their potential influence on the type I error rate. Different estimation methods within NONMEM were tried. When the first-order conditional estimation method with interaction (FOCE INTER) was used the estimated type I error rates for inclusion of a covariate effect (i) on the interindividual variability, or (ii) on the residual error variability, were in agreement with the type I error rate expected under the assumption that the model approximations made by the estimation method are negligible. When the residual error variability was increased, the type I error rates for (iii) inclusion of covariance between etaCL-etaV were inflated if the underlying residual distribution was lognormal, or if a normal distribution was combined with too little information in the data (too few samples per subject or sampling at uninformative time-points). For inclusion of (iv) etaV, the type I error rates were affected by the underlying residual error distribution; with a normal distribution the estimated type I error rates were close to the expected, while if a non-normal distribution was used the type I errors rates increased with increasing residual variability. When the first-order (FO) estimation method was used the estimated type I error rates were higher than the expected in most situations. For the FOCE INTER method, but not the FO method, the LR test is appropriate when the underlying assumptions of normality of residuals, and of enough information in the data, hold true. Deviations from these assumptions may lead to inflated type I error rates.</abstract><cop>Dordrecht</cop><pub>Springer</pub><pmid>12449498</pmid><doi>10.1023/A:1020254823597</doi><tpages>19</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1567-567X |
ispartof | Journal of pharmacokinetics and pharmacodynamics, 2002-06, Vol.29 (3), p.251-269 |
issn | 1567-567X 1573-8744 |
language | eng |
recordid | cdi_proquest_miscellaneous_72697947 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | Analysis of Variance Biological and medical sciences Computer Simulation - statistics & numerical data General pharmacology Humans Injections, Intravenous - statistics & numerical data Likelihood Functions Medical sciences Models, Statistical Nonlinear Dynamics Normal distribution Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions Pharmacology. Drug treatments Studies |
title | Assessment of type I error rates for the statistical sub-model in NONMEM |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T18%3A21%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20type%20I%20error%20rates%20for%20the%20statistical%20sub-model%20in%20NONMEM&rft.jtitle=Journal%20of%20pharmacokinetics%20and%20pharmacodynamics&rft.au=W%C3%84HLBY,%20Ulrika&rft.date=2002-06-01&rft.volume=29&rft.issue=3&rft.spage=251&rft.epage=269&rft.pages=251-269&rft.issn=1567-567X&rft.eissn=1573-8744&rft_id=info:doi/10.1023/A:1020254823597&rft_dat=%3Cproquest_pubme%3E2157705731%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=757038824&rft_id=info:pmid/12449498&rfr_iscdi=true |